Home-based versus clinic-based care for patients starting antiretroviral therapy with low CD4+ cell counts: Findings from a cluster-randomized trial

AIDS

Volumn 28, Issue 4, 2014, Pages 569-576

  Woodd, Susannah L ^a   Grosskurth, Heiner ^a,b   Levin, Jonathan ^b   Amuron, Barbara ^b   Namara, Geoffrey ^b   Birunghi, Josephine ^c   Coutinho, Alex ^d   Jaffar, Shabbar ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b MRC/UVRI   (Uganda)

^c THE AIDS SUPPORT ORGANIZATION   (Uganda)

^d Infectious Diseases Institute   (Uganda)

Author keywords

Africa; Antiretroviral therapy; HIV; Home based; Jinja; late presentation; survival; Uganda

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL SUPERVISION; CONTROLLED STUDY; FEMALE; HEALTH CARE DELIVERY; HOME CARE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MEDICAL STAFF; MIDDLE AGED; MORTALITY; PRIORITY JOURNAL; STAFF; SURVIVAL RATE; UGANDA; VIRUS LOAD; VOLUNTARY WORKER;

ADULT; AMBULATORY CARE; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HOME CARE SERVICES; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; SURVIVAL ANALYSIS; UGANDA;

EID: 84893216006     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000056     Document Type: Article

References (18)

1. World Health Organisation, UNAIDS, UNICEF. Global update on HIV treatment 2013: Results, impact and opportunities. Geneva, Switzerland: WHO; 2013.
2. World Health Organisation. World Health Statistics 2010. Geneva, Switzerland: WHO; 2010.
3. Jaffar S, Amuron B, Foster S, Birungi J, Levin J, Namara G, et al. Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: A cluster-randomised equivalence trial. Lancet 2009; 374:2080-2089.
4. Wandeler G, Keiser O, Pfeiffer K, Pestilli S, Fritz C, Labhardt ND, et al. Outcomes of antiretroviral treatment programs in rural Southern Africa. J Acquir ImmuneDefic Syndr 2012; 59:e9-e16.
5. Mills EJ, Bakanda C, Birungi J, Mwesigwa R, Chan K, Ford N, et al. Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: Evidence from a large cohort in Uganda. AIDS 2011; 25:851-855.
6. May M, Boulle A, Phiri S, Messou E, Myer L, Wood R, et al. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: A collaborative analysis of scale-up programmes. Lancet 2010; 376:449-457.
7. Lawn SD, Little F, Bekker L-G, Kaplan R, Campbel E, Orrell C, et al. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS 2009; 23:335-342.
8. Gupta A, Nadkarni G, Yang W-T, Chandrasekhar A, Gupte N, Bisson GP, et al. Early mortality in adults initiating antiretroviral therapy (ART) in low-and middle-income countries (LMIC): A systematic review and meta-analysis. PLoS ONE 2011; 6:e28691.
9. Brinkhof MWG, Dabis F, Myer L, Bangsberg DR, Boulle A, Nash D, et al. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ 2008; 86:559-567.
10. Amuron B, Namara G, Birungi J, Nabiryo C, Levin J, Grosskurth H, et al. Mortality and loss-to-follow-up during the pretreatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health 2009; 9:290.
11. Jaffar S, Amuron B, Birungi J, Namara G, Nabiryo C, Coutinho A, et al. Integrating research into routine service delivery in an antiretroviral treatment programme: Lessons learnt from a cluster randomized trial comparing strategies of HIV care in Jinja, Uganda. Trop Med Int Health 2008; 13:795-800.
12. Amuron B, Levin J, Birunghi J, Namara G, Coutinho A, Grosskurth H, Jaffar S. Mortality in an antiretroviral therapy programme in Jinja, south-east Uganda: A prospective cohort study. AIDS Res Ther 2011; 8:39.
13. Cornell M, McIntyre J, Myer L. Men and antiretroviral therapy in Africa: Our blind spot. Trop Med Int Health 2011; 16:828-829.
14. Brinkhof MWG, Boulle A, Weigel R, Messou E, Mathers C, Orrell C, et al. Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: Comparison with HIV-unrelated mortality. PLoS Med 2009; 6:e1000066.
15. MacPherson P, Moshabela M, Martinson N, Pronyk P. Mortality and loss to follow-up among HAART initiators in rural South Africa. Trans Royal Soc Trop Med Hygiene 2009; 103:588-593.
16. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: Comparison between lowincome and high-income countries. Lancet 2006; 367:817-824.
17. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: A systematic review. PLoS Med 2011; 8:e1001056.
18. World Health Organisation. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection-recommendations for a public health approach. Geneva, Switzerland: WHO; 2013.